This is a working overview of cjc-1295, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-23 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
== Selected publications == Dendrosome: Dendrosomes: a novel family of vehicles for transfection and therapy. Journal of Chemical Technology & Biotechnology. Volume 75 Issue 10, Pages 919 - 922 (2000) Dendrosomes as novel gene porters-III. Journal of Chemical Technology & Biotechnology Volume 83 Issue 6, Pages 912 - 920 (2008) Structural biology: Functional and structural characterization of a novel member of the natriuretic family of peptides from the venom of Pseudocerastes persicus. FEBS Letters Volume 557 Issue 1-3, Pages 104-108 (2004) Solution structure of long neurotoxin NTX-1 from the venom of Naja naja oxiana by 2D-NMR spectroscopy. European Journal of Biochemistry Volume 271 Issue 23-24 Pages 4950-4957 (2004) Biomaterials: Synthesis and thermal behavior of triblock copolymers from L-lactide and ethylene glycol with long center PEG block. Journal of Applied Polymer Science Volume 68 Issue 12 Pages 1949-1954 (1998) Synthesis and characterization of novel biodegradable triblock copolymers from L-lactide, glycolide, and PPG. Journal of Applied Polymer Science Volume 73 Issue 5 Pages 633-637 (1999) Synthesis and characterization of ABA triblock and novel multiblock copolymers from ethylene glycol, L-lactide, and epsilon-caprolactone. Journal of Applied Polymer Science Volume 83 Issue 10 Pages 2072-2081 (2002) Mass preparation and characterization of alginate microspheres. Process Biochemistry Volume 35 Issue 9 Pages 885-888 (2000) Membranes: A simple method for preparation of immuno-magnetic liposomes.
Cohen (1952), former co-owner of the Boston Celtics and the Brooklyn Nets; former chairman and CEO of the Madison Square Garden Corporation Lawrence K. Grossman (1952), president of PBS 1976–1984 and NBC News 1985–1988 Richard Wald (1952), former president of NBC News 1973–1977 Robert A. Belfer (1955), oilman and philanthropist, namesake of the Belfer Center for Science and International Affairs at Harvard University Thomas Ludlow Chrystie II (1955), first chief financial officer of Merrill Lynch & Company and creator of the Cash Management Account Alfred Lerner (1955), chairman of MBNA Bank and ex-owner of the Cleveland Browns Richard Ravitch (1955), chairman of the Metropolitan Transportation Authority and the Bowery Savings Bank Sid Sheinberg (1955), head of Universal Pictures Barry F. Sullivan (1955), chairman and CEO of First Chicago Bank, deputy mayor of New York City under David Dinkins Edward Botwinick (1956), IT entrepreneur and inventor, co-founder of Timeplex Franklin A. Thomas (1956), former president of The Ford Foundation James R. Barker (1957), chairman of Interlake Steamship Company, former chairman and CEO of Moore-McCormack Peter L.
The samples were originally taken to test for preventable diseases, but with the advance in genomic sequencing technologies many samples are being kept for DNA identification and research, increasing the possibility that more children will be opted out of newborn screening from parents who see the kept samples as a form of research done on their child.
Sources: en.wikipedia.org
Directed assembly of micro- and nano-structures are methods of mass-producing micro to nano devices and materials. Directed assembly allows the accurate control of assembly of micro and nano particles to form even the most intricate and highly functional devices or materials.
New York: Touchstone (Simon & Schuster). ISBN 0-671-70625-X. The link is to the 2004 edition, pages differ, but content the same. Parry, Dan (2009). Moonshot: The Inside Story of Mankind's Greatest Adventure. Chatham, United Kingdom: Ebury Press. ISBN 978-0-09-192837-7. Pekkanen, Saadia M. "Governing the New Space Race." AJIL Unbound 113 (2019): 92–97. online, role of international law. Polmar, Norman; Timothy M. Laur (1990). Strategic Air Command: People, Aircraft, and Missiles (2 ed.). Baltimore: Nautical and Publishing Company of America. ISBN 0-933852-77-0. Poole, Robert (2008). Earthrise: How Man First Saw the Earth. New Haven, Connecticut: Yale University. ISBN 978-0-300-13766-8. Portree, David S.F. (March 1995). "Mir Hardware Heritage" (PDF). Johnson Space Center Reference Series. NASA Reference Publication 1357. Houston TX: NASA. Archived from the original (PDF) on March 23, 2021. Retrieved January 8, 2023. Schefter, James (1999). The Race: The uncensored story of how America beat Russia to the Moon. New York: Doubleday. ISBN 0-385-49253-7. Schmitz, David F. (1999). "Cold War (1945–91): Causes". In Whiteclay Chambers, John (ed.). The Oxford Companion to American Military History. Oxford University Press. ISBN 0-19-507198-0. Seamans, Robert C. Jr. (1967). "Findings, Determinations And Recommendations". Report of Apollo 204 Review Board. NASA History Office. Archived from the original on November 5, 2015. Retrieved April 28, 2010. Siddiqi, Asif A. (2018). Beyond Earth: A Chronicle of Deep Space Exploration, 1958–2016 (PDF). Washington D.C.: NASA History Division. p.
According to the UN Department of Economic and Social Affairs, Pakistan has the sixth-largest diaspora globally. Approximately 7 million Pakistanis reside abroad, mainly in the Middle East, Europe, and North America. Pakistan ranks 10th globally for remittances sent home. Saudi Arabia is the largest source of remittances, contributing $5.9 billion as of 2016. The term Overseas Pakistani is officially recognised by the Government of Pakistan, with the Ministry of Overseas Pakistanis and Human Resource Development addressing their needs, welfare, and issues. Overseas Pakistanis constitute the second-largest source of foreign exchange remittances to Pakistan, with remittances increasing by over 100% from US$8.9 billion in 2009–10 to US$19.9 billion in 2015–16.
Sources: en.wikipedia.org
Growth over the corneal centre. Reduced vision due to corneal distortion. Documented growth. Symptoms of discomfort. Cosmesis. Surgery is usually performed under local anaesthetic with light sedation as day surgery. The pterygium is stripped carefully off the surface of the eye. If this is all that is done, the pterygium regrows frequently. The technique with the lowest recurrence rate uses an autotransplantation of conjunctiva from under the eyelid. This is placed over the defect remaining from the removed pterygium. The graft can be stitched in place, which is time-consuming, and painful for the patient afterwards. An alternative is the use of tissue adhesive fibrin glue. A Cochrane review including 14 studies and last updated October 2016, found that using fibrin glue when doing conjunctival autografting was associated with a reduced likelihood of the pterygium recurring compared with sutures. The review found that operations may take less time but fibrin glue may be associated with more complications (for example, rupture, shrinking, inflammation, granuloma). A 3-year clinical study on the application of collagen matrix as excision site grafts showed significantly improved surgery success rates. The mechanism of the collagen matrix graft (commercially available as ologen) works by promoting healthy cell growth into the matrix, thus preventing conjunctiva overgrowth that can cover the iris.
Feduccia's frill argument was followed up in several other publications, in which researchers interpreted the filamentous impressions around Sinosauropteryx fossils as remains of collagen fibres rather than primitive feathers. Since the structures are clearly external to the body, these researchers have proposed that the fibres formed a frill on the back of the animal and underside of its tail, similar to some modern aquatic lizards. The absence of feathers would refute the proposal that Sinosauropteryx is the most basal known theropod genus with feathers, and also raise questions about the current theory of feather origins itself. It calls into question the idea that the first feathers evolved not for flight but for insulation, and that they made their first appearance in relatively basal dinosaur lineages that later evolved into modern birds. Most researchers have disagreed with the identification of the structures as collagen or other structural fibres. Notably, the team of scientists that reported the presence of pigmentation cells in the structures argued that their presence proved the structures were feathers, not collagen, because collagen does not contain pigment. Gregory S. Paul reidentified what the collagen hypothesis's proponents consider a body outline outside of the fibres as an artefact of preparation: breakage and brushed-on sealant have been misidentified as the outline of the body. The hypothesis that the structures were collagen fibers was closely analyzed and disproven by a 2017 paper published by Smithwick et al.
== Mathematical analysis of the FcRn mechanism == Antibody binding, salvage and recycling by FcRn is an important part of modelling antibody pharmacokinetics. In fact, besides target-mediated drug dispostiion (TMDD), it is one of the most important factors mediating (non-specific) antibody elimination. Such a mechanism lies at the core of most physiology-based pharmacokinetic (PBPK) models of antibodies, see e.g. Garg and Balthasar, 2007; Shah and Betts, 2012; Niederal et al., 2018; Glassman and Balthasar, 2019; de Witte et al., 2023; De Sutter et al. (2024). Some of first steps towards understanding and gaining mathematical insight into the FcRn mechanism was taken by Patsatzis et al. (2022), using the computational singular perturbation (CSP) approach to analyse a minimal FcRn model. This preliminary work was extended and deepend by Katai et al. (2024) using the method of matched asymptotic expansions. This latter work constituted an asymptotic analysis of the mechanism in the high binding affinity limit, i.e. where binding was assumed to be an order of magnitude faster than all other processes. This resulted in a three-tiered scaling framework for non-saturating doses, with binding on the fastest time scale (typically over seconds or minutes), all other cellular process on an intermediate time scale (hours) and a long 'effective' elimination time scale (days, weeks).
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.